HERON THERAPEUTICS, INC. /DE/ (HRTX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$0.32

From 52W high−79.21%

Volume3.65M

Market cap$58.80M

P/E (TTM)—

P/S (TTM)0.4x

Div yield—

Key dataSep 18, 2026

Open

$0.32

From 52W high

−79.21%

Volume

3.65M

Market cap

$58.80M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.9x

P/E (TTM)

—

RSI (14)

37.5

MomentumView details →

1D Return

−1.90%

YTD Return

−76.02%

SummaryUpdated Jun 1, 2026

Heron Therapeutics, Inc. (NASDAQ:HRTX) is a San Diego-based biotechnology company founded in 1983 that develops specialized treatments for unmet medical needs in oncology and acute care settings. Originally known as A.P. Pharma, Inc., the company rebranded to Heron Therapeutics in 2014 to reflect its focus on innovative drug delivery technologies. The company has evolved from a development-stage biotechnology firm to a commercial-stage pharmaceutical company with multiple approved products generating over $144 million in annual revenue as of 2024.

Ask drillr about HERON THERAPEUTICS, INC. /DE/ →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−5.9x

EV/Sales

1.1x

P/S (TTM)

0.4x

P/B (TTM)

8.5x

ProfitabilityView details →

Gross Margin

70.07%

Net Margin

−22.52%

EBITDA Margin

−18.42%

ROE (TTM)

−492.89%

ROA (TTM)

−13.50%

Asset Turnover

0.61x

GrowthView details →

Revenue YoY

+0.99%

EPS YoY

—

FCF YoY

+58.91%

Revenue CAGR 3Y

+12.89%

EPS CAGR 3Y

−34.68%

EBITDA YoY

—

MomentumView details →

1D Return

−1.90%

YTD Return

−76.02%

1Y Return

−74.65%

RSI (14)

37.5

vs 50D SMA

−19.23%

vs 200D SMA

−63.30%

Capital & dividendView details →

Debt/Equity

21.48x

Current Ratio

2.49x

Quick Ratio

1.51x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

−500.00%

Beats (12Q)

6/12

Next Q EPS Est

−$0.03

Avg Surprise (4Q)

−191.87%

Rev Surprise

−10.72%

Financials snapshotView financials →

Revenue (TTM)

151.18M

Net Income (TTM)

−34.05M

Op. CF (TTM)

−11.61M

Next earningsNov 3, 2026 →

Latest newsMore news →

Heron Therapeutics reported Q2 2026 total net revenue of $37.7 million, up 1.3% year-over-year, with a net loss of $5.5 million and diluted EPS of -$0.03.42d ago

The U.S. District Court for the District of Delaware issued a decision in patent litigation between Heron Therapeutics and Azurity Pharmaceuticals, holding Heron's asserted patents for CINVANTI invalid.110d ago

Similar companies

PDS Biotechnology CorporationPDSB NOMAD Power Solutions, Inc.NMAD eXoZymes, Inc.EXOZ Xilio Therapeutics, Inc.XLO MiNK Therapeutics, Inc.INKT Fortress Biotech, Inc.FBIOP Find similar companies →

Latest newsMore news →

Heron Therapeutics reported Q2 2026 total net revenue of $37.7 million, up 1.3% year-over-year, with a net loss of $5.5 million and diluted EPS of -$0.03.42d ago The U.S. District Court for the District of Delaware issued a decision in patent litigation between Heron Therapeutics and Azurity Pharmaceuticals, holding Heron's asserted patents for CINVANTI invalid.110d ago